Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18915035 | EFFICIENT SYNTHESIS AND ASSEMBLY METHOD FOR LARGE FRAGMENT DNA BASED ON PROGRAMMABLE NUCLEASE ARGONAUTE | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18715637 | RECOMBINANT COLLAGEN AND PREPARATION METHOD AND USE THEREOF | May 2024 | May 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18493307 | SYNTHETIC GENOME | October 2023 | April 2025 | Allow | 18 | 3 | 0 | No | No |
| 18332464 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | June 2023 | January 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18321475 | SYNTHETIC GENOME | May 2023 | October 2024 | Abandon | 16 | 2 | 1 | No | No |
| 18037065 | Fluorescent Fusion Based Heterologous Peptide Production | May 2023 | August 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18168357 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | February 2023 | February 2025 | Allow | 24 | 4 | 0 | Yes | No |
| 17610974 | SYNTHETIC GENOME | November 2021 | May 2025 | Allow | 43 | 2 | 0 | No | No |
| 17501421 | HIGH-EFFICACY CRISPRI SYSTEM AND STRONG SYNTHETIC PROMOTERS FOR ALPHAPROTEOBACTERIA AND GAMMAPROTEOBACTERIA | October 2021 | March 2025 | Allow | 41 | 4 | 1 | Yes | No |
| 17440777 | FUSION PROTEIN FOR ENHANCING GENE EDITING AND USE THEREOF | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17464691 | Novel tracrRNA system for Cas9 | September 2021 | April 2025 | Abandon | 44 | 5 | 1 | Yes | No |
| 17382945 | METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED "CTL-seq" (CRISPR Tag Linear-seq) | July 2021 | May 2025 | Abandon | 46 | 4 | 1 | Yes | No |
| 17251975 | Method for Producing Selenoneine | July 2021 | January 2025 | Allow | 49 | 2 | 0 | No | No |
| 17368369 | NON-TOXIC CAS9 ENZYME AND APPLICATION THEREOF | July 2021 | April 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17355638 | TUNNELING NANOTUBE CELLS AND METHODS OF USE THEREOF FOR DELIVERY OF BIOMOLECULES | June 2021 | February 2025 | Abandon | 44 | 4 | 0 | No | No |
| 17214839 | Method For Creating Reference Cell Lines With Simultaneous Genetic Variants And Accurate Quantification Of Alelle Frequency | March 2021 | January 2025 | Abandon | 45 | 3 | 1 | No | No |
| 17203129 | NATURAL GUIDE ARCHITECTURES AND METHODS OF MAKING AND USING THE SAME | March 2021 | February 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17042170 | GENETIC SCREENING METHOD OF NEGATIVE REGULATORY FACTORS OF STREPTOMYCES BIOSYNTHESIS GENE CLUSTER | September 2020 | March 2025 | Abandon | 53 | 3 | 0 | No | No |
| 16073005 | MEANS AND METHODS FOR SELECTING TRANSFORMED CELLS | August 2020 | October 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16535565 | ALTERNATIVE NUCLEOTIDE FLOWS IN SEQUENCING-BY-SYNTHESIS METHODS | August 2019 | February 2025 | Allow | 60 | 5 | 0 | No | No |
| 16238386 | NEGATIVE SELECTION AND STRINGENCY MODULATION IN CONTINUOUS EVOLUTION SYSTEMS | January 2019 | April 2025 | Allow | 60 | 2 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner RYAN, DOUGLAS CHARLES works in Art Unit 1635 and has examined 19 patent applications in our dataset. With an allowance rate of 42.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner RYAN, DOUGLAS CHARLES's allowance rate of 42.1% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RYAN, DOUGLAS CHARLES receive 2.84 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by RYAN, DOUGLAS CHARLES is 44 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +24.3% benefit to allowance rate for applications examined by RYAN, DOUGLAS CHARLES. This interview benefit is in the 74% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 12.5% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.